Despite innovative treatments for chronic spontaneous urticaria (CSU), gaps in access and prescribing variations persist. Analysis Group’s real-world evidence analysis of a large US insurance claims database reveals significant disparities in healthcare utilization and a concerning reliance on systemic corticosteroids and emergency services. Explore their findings to understand how variations in advanced therapy access impact CSU management and identify opportunities to improve patient outcomes.